Calliditas Therapeutics AB Share Holder Equity 2020-2024 | CALT

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Calliditas Therapeutics AB share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Calliditas Therapeutics AB share holder equity from 2020 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Zoetis (ZTS)	$89B
Takeda Pharmaceutical (TAK)	$47.2B
Merck (MKGAF)	$23.7B
Astellas Pharma (ALPMY)	$22.1B
Summit Therapeutics (SMMT)	$17.8B
Sandoz Group AG (SDZNY)	$17.6B
United Therapeutics (UTHR)	$15.2B
Shionogi (SGIOY)	$13.1B
Neurocrine Biosciences (NBIX)	$12.1B
Catalent (CTLT)	$10.9B
Orion OYJ (ORINY)	$7.4B
Revolution Medicines (RVMD)	$7.4B
Jazz Pharmaceuticals (JAZZ)	$6.8B
Ionis Pharmaceuticals (IONS)	$6.2B
Hikma Pharmaceuticals Plc (HKMPF)	$5.7B
Madrigal Pharmaceuticals (MDGL)	$5.1B
Corcept Therapeutics (CORT)	$4.4B
Crinetics Pharmaceuticals (CRNX)	$4.2B
Dyne Therapeutics (DYN)	$3.4B
PTC Therapeutics (PTCT)	$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)	$2.7B
Arrowhead Pharmaceuticals (ARWR)	$2.6B
Catalyst Pharmaceuticals (CPRX)	$2.4B
Soleno Therapeutics (SLNO)	$2.1B
Recursion Pharmaceuticals (RXRX)	$1.9B
Centessa Pharmaceuticals (CNTA)	$1.8B
BioCryst Pharmaceuticals (BCRX)	$1.6B
Xencor (XNCR)	$1.6B
Harrow (HROW)	$1.6B
Cassava Sciences (SAVA)	$1.5B